ArticleiScience2026
Exemestane increases the number and improves the morphology of cultured pre-antral follicles from transmasculine ovarian cortical tissue.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To enhance fertility preservation options, it would be beneficial to develop culture platforms starting from cryopreserved-thawed ovarian cortical tissue. Importantly, ovarian cortical tissue from cisgender females (cOVA) and transmasculine individuals (tOVA) respond differently to culture and may require specific conditions to support optimal folliculogenesis. We explored the role of CYP19A1-inhibitor exemestane on the emergence of pre-antral follicles during culture to equalize the use of cOVA and tOVA. We compared follicular growth, morphology, and distribution between cOVA and tOVA using immunofluorescence and hormonal quantification. The inhibitor reduced the estrogen levels in both OVA types, while enhancing follicular morphology of tOVA. Moreover, treatment with exemestane decreased STAR expression in tOVA regulating progesterone locally. The addition of exemestane during this initial culture period may prove beneficial to obtain pre-antral follicles from tOVA more comparable to cOVA. These findings represent a step toward optimizing culture conditions to support early folliculogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.